Pancreatic Cancer Research

ResearcherAzienda Ospedaliero-Universitaria CareggiActive in the last 2 years

Lorenzo Antonuzzo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3349-5604; OpenAlex author ID A5002745641. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
36
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: 4 papers · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 9

  1. The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 20… Last author DOI 10.1186/s13045-026-01834-2↗
  2. Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score… Co-author DOI 10.1016/j.esmoop.2025.105874↗
  3. Transcriptomic analysis on pancreatic adenocarcinoma patients uncovers KRAS-mediated PPAR pathway alteration. Co-author DOI 10.3389/fonc.2025.1613773↗
  4. The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.6111↗
  5. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary a… Co-author DOI 10.1016/j.esmoop.2022.100777↗
  6. KRAS-related miR-143 expression is associated with lymph node involvement and correlates with outcome in pancreatic adenocarcinoma patients. Last author DOI 10.3389/fonc.2023.1295936↗
  7. Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine. Co-author DOI 10.3390/cancers15020416↗
  8. Isoforms of the orphan nuclear receptor COUP‑TFII differentially modulate pancreatic cancer progression. Co-author DOI 10.3892/ijo.2022.5345↗
  9. Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study). Co-author DOI 10.3390/curroncol28030164↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elisa Giommoni · 5 shared papers, 2021–2026 · strength 0.93
  2. Andrea Galli · 4 shared papers, 2022–2026 · strength 0.85
  3. Serena Pillozzi · 4 shared papers, 2021–2026 · strength 0.83
  4. Daniele Lavacchi · 3 shared papers, 2023–2026 · strength 0.72
  5. Simone Polvani · 3 shared papers, 2022–2025 · strength 0.53
  6. Francesco Di Costanzo · 2 shared papers, 2021–2023 · strength 0.35
  7. Mario Scartozzi · 2 shared papers, 2023–2025 · strength 0.32
  8. Letizia Procaccio · 2 shared papers, 2023–2025 · strength 0.32
  9. Andrea Pretta · 2 shared papers, 2023–2025 · strength 0.32
  10. Caterina Vivaldi · 2 shared papers, 2021–2025 · strength 0.30
  11. Giampaolo Tortora · 2 shared papers, 2021–2025 · strength 0.30
  12. Vanja Vaccaro · 2 shared papers, 2021–2023 · strength 0.25
  13. Guido Giordano · 2 shared papers, 2021–2023 · strength 0.25
  14. Giuseppe Defazio · 1 shared paper, 2025 · strength 0.24
  15. Nai‐Jung Chiang · 1 shared paper, 2025 · strength 0.18
  16. Wen‐Chi Chou · 1 shared paper, 2025 · strength 0.18
  17. Yung‐Yeh Su · 1 shared paper, 2025 · strength 0.18
  18. Li‐Tzong Chen · 1 shared paper, 2025 · strength 0.18
  19. Giovanni Trovato · 1 shared paper, 2025 · strength 0.18
  20. Monica Niger · 1 shared paper, 2025 · strength 0.18
  21. Lisa Salvatore · 1 shared paper, 2025 · strength 0.18
  22. Li‐Yuan Bai · 1 shared paper, 2025 · strength 0.18
  23. Yan‐Shen Shan · 1 shared paper, 2025 · strength 0.18
  24. Simona Casalino · 1 shared paper, 2023 · strength 0.13
  25. Valeria Merz · 1 shared paper, 2023 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.